ABL	V-abl Abelson murine leukaemia viral oncogene homolog 1
Akt	serine/threonine kinase 1
ALK	anaplastic lymphoma kinase
ALL	acute lymphoblastic leukaemia
AML	acute myeloid leukaemia
ATM	ATM serine/threonine kinase
ATP	adenosine triphosphate
BCR	ABL1-breakpoint cluster region and V-abl Abelson murine leukaemia viral oncogene homolog
BRAF	gene encoding protein B-Raf
BRCA1	breast cancer 1 gene
BRCA2	breast cancer 2 gene
CCyR	complete cytogenetic response
CDK4/6	cyclin-dependent kinase
CHR	complete haematologic response
c-KIT	tyrosine-protein kinase KIT
c-MET	hepatocyte growth factor receptor
CML-BP	chronic myeloid leukaemia plastic phase
CML	chronic myeloid leukaemia
CNS	central nervous system
COG	Children’s Oncology Group
CSF-1R	Colony stimulating factor 1 receptor
EGFR	epidermal growth factor receptor
ELN	European Leukaemia Net
ERK1/2	extracellular signal-regulated kinases
EsPhALL	European Study of Postinduction Treatment of Ph-Positive ALL
EZH2	enhancer of zeste homolog 2
FDA	Food and Drug Administration
FGFR1	fibroblast growth factor receptor 1
FGFR2	fibroblast growth factor receptor 2
FGFR3	fibroblast growth factor receptor 3
FGFR4	fibroblast growth factor receptor 4
FLT3	cluster of differentiation antigen 135
GCT	germ cell tumour
GIST	gastrointestinal stromal tumour
HER2	human epidermal growth factor receptor 2
HRAS	v-Ha-ras Harvey rat sarcoma viral oncogene homolog
HSCT	haematopoietic stem cell transplantation
IRIS	International Randomised Study of Interferon and STI571
KIT	tyrosine-protein kinase KIT cluster of differentiation 117
MATCH	Molecular Analysis for Therapeutic Choice
MAPK	mitogen-activated protein kinase
MET	MET proto-oncogene, tyrosine kinase receptor
MM-GBMV	molecular mechanics—generalised Born molecular volume
MMR	major molecular response
NCI	National Cancer Institute
NCI-MATCH	National Cancer Institute—Molecular Analysis for Therapeutic Choice
NRTK	non-receptor protein tyrosine kinase
NSCLC	non-small-cell lung cancer
OS	overall survival
P loop	phosphate binding loop
P13K/mTOR	intracellular signalling pathway
pan-TRK	family of receptor tyrosine kinases
PARP	poly (ADP-ribose) polymerase
PDGFRα	platelet-derived growth factor receptor alpha
PDGFRβ	platelet-derived growth factor receptor beta
Ph-like ALL	Philadelphia chromosome-like acute lymphoblastic leukaemia
Ph+ ALL	Philadelphia chromosome acute lymphoblastic leukaemia
PI3K	phosphoinositide 3-kinase
PI3K/mTOR	phosphatidylinositol 3-kinase/mammalian target of rapamycin kinase
PTK	protein tyrosine kinase
Rb	retinoblastoma
RAF	proto-oncogene
RAS	rat sarcoma virus protein family
Rb	retinoblastoma
RET	“rearranged during transfection” proto-oncogene
RR	relative resistance
ROS1	ROS proto-oncogene 1, tyrosine kinase receptor
RTK	receptor protein tyrosine kinase
SMARCB1	SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, Subfamily B, Member 1
SMARCA4	SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, Subfamily A, Member 4
SRC	Src proto-oncogene, non-receptor tyrosine kinase
STAMP	specifically targeting the myristoyl pocket
STI571	imatinib
TKI	tyrosine kinase inhibitor
TRKA	tropomyosin receptor kinase A
TRKB	tropomyosin receptor kinase B
TRKC	tropomyosin receptor kinase C
TSC1	Tuberous sclerosis 1
TSC2	Tuberous sclerosis 2
UK	United Kingdom
USA	United States of America
VEGFR	vascular endothelial growth factor
VEGFR2	vascular endothelial growth factor 2
VEGFR3	vascular endothelial growth factor 3